您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2022 - 03 - 16
点击次数: 0
所属职位:
所属公司: 驯鹿医疗
个人简介:
郑彪博士毕业于浙江大学医学院医学系;获上海复旦大学医学院免疫学硕士及伦敦大学 (King’s College, University of London) 免疫学博士学位。曾在美国马里兰大学医学院 (University of Maryland School of Medicine) 及杜克大学医学中心 (Duke University Medical Center) 任教。随后任职于美国贝勒医学院 (Baylor College of Medicine), 为该校病理和免疫系终身教授。在葛兰索史克 (GlaxoSmithKline) 研发中心负责免疫学研究工作。曾任美国强生公司(Janssen Pharmaceuticals, Johnson & Johnson) 全球副总裁, 负责亚太地区免疫领域创新药物研发,包括免疫调节机制、肿瘤免疫、及自身免疫性疾病。郑彪博士现任驯鹿医疗首席科学官。        郑彪教授学术著作丰厚,其中多篇发表在Nature和Science等世界顶尖杂志上。在马里兰大学、杜克大学及贝勒医学院工作期间获得多项重大科研基金,包括美国NIH科研基金、白血病与淋巴瘤协会基金、美国关节炎基金会、美国心脏研究协会基金、美国衰老研究联盟基金等。在药物研发方面,从新药筛选、靶点研究、疾病模型、临床前及临床试验等方面积累了重要的经验,对新药开发全过程有深刻的认识。Dr. Biao Zheng graduated with a medical degree from Zhejiang University School of Medicine. He received his PhD in Immunology from King’s College, University of London. Dr. Zheng served at the faculty of University of Maryland School of Medicine and Duke University Medical Center. He was a tenured professor in the Department of Pathology and Immunology, Baylor College of Medicine. Dr. Zheng joined GlaxoSmithKline R&D Center in 2010 as the head of Immunological Discovery Sciences. He was a global vice president of the Immunology Therapeutic Area, Janssen Pharmaceuticals, and Johnson & Johnson Innovation Center, Asia Pacific, responsible for the innovative immunological drug pipeline in the region. Dr. Zheng is now the Chief Scientific Officer at IASO Biotherapeutics.Dr. Zheng is an experienced physician scientist, drug hunter, and professor with a demonstrated history working both in academia and pharmaceutical industry. He has more than thirty years of experience in biomedical research and drug discovery. He has published extensively in world top journals including Nature and Science. His major areas of research and development include autoimmune diseases, immuno-oncology, and novel vaccine development.
发布时间: 2022 - 03 - 16
点击次数: 0
所属职位: 副总经理&首席科学官
所属公司: 中源协和细胞基因工程股份有限公司
个人简介:
北京航空航天大学生物医学工程学士、空间生命科学硕士,德国海因里希海涅杜塞尔多夫大学(Heinrich-Heine-Universität Düsseldorf)干细胞与再生医学专业博士,天津医科大学双聘教授,国家干细胞工程产品产业化基地研究员,高级工程师。曾任颐昂生物科技(北京)有限公司总裁兼首席执行官,中源协和总裁助理、Biotechnology Transfer Center of VCANBIO USA研发副总等。在德国期间曾任德国波恩科技大学讲师、德国宇航局亥姆霍兹中心助理研究员和意大利帕勒莫大学访问学者等。主持或参加了国家科技部重点研发专项、欧盟EU、德国教育科技部BMBF、德国研究基金会DFG等资助的细胞技术相关研究项目,累计在干细胞与再生医学领域发表高水平SCI论文十余篇,发明专利若干项。目前担任国际干细胞研究协会ISSCR会员、国际细胞治疗协会ISCT会员、德国干细胞协会会员,国家干细胞与再生医学产业技术创新战略联盟副秘书长,湖北省干细胞临床研究专家委员会委员,云南省干细胞临床研究专家委员会委员,天津市干细胞再生医学转化企业重点实验室主任,天津市血液细胞治疗技术企业重点实验室主任,中国细胞生物学学会会员,德国莱茵论坛理事,《药学进展》杂志等编委,Current Stem Cell Research&Therapy等杂志的审稿人。入选天津131人才计划,3551光谷人才计划,首批A类天津绿卡获得者。 Dr. Zhang Yu is the SVP&CSO of Vcanbio Cell&Gene Engineering Co.,Ltd (A listed company on Shanghai A stock). Prior to join Aeon, Dr. Zhang was president and CEO of Aeon Therapeutics, a joint-venture biotech company between Eureka Therapeutics Inc. and Vcanbio; assistant president in Vcanbio. Dr. Zhang received his B.S. in Bioengineering and M.S. in Biomedical Engineering from Beihang University, and a Ph.D. in Stem Cell and Regenerative Medicine from Heinrich-Heine-Universität Düsseldorf. In the period of Germany, he worked in Rhine Forum, University of Applied Sciences Bonn-Rhein-Sieg, and was a visiting scholar in German Aerospace Center and University of Palermo. He is a member of German Society of Stem Cell, Chinese Society of Cell Biology, and reviewer of several cell therapy journals, e.g. Current Stem Cell Research&Therapy. Dr. Zhang was the winner of “131 talent plan” and “Tianjin Green Card Plan”.
发布时间: 2022 - 03 - 16
点击次数: 0
所属职位: 董事长
所属公司: 上海优卡迪生物医药科技有限公司
个人简介:
1984年本科毕业于上海第一医学院医学专业,1996年获得加拿大阿尔伯塔大学医学微生物学与免疫学专业博士学位。1999年担任美国犹他大学化学制药与制药系和生物工程系科研副教授,和著名的药剂界学术和工业界先驱Sun Wang Kim教授和Henry Kopecek教授合作,建立了当时前沿基因治疗技术和产品的评估和转化平台。2000年加入美国日东电工技术公司担任公司副总裁,专注于生物材料、生物技术和跨界技术模块化的生物药品的开发、转化、产业化和商业化。2004年创建创新生命科学公司,加速NDT公司技术和产品的商业化发展。2012年回国,担任华东师范大学生物医学工程和技术研究所所长,现任上海药剂专委会委员、上海医用材料专委会会员等。2015年创建上海优卡迪生物医药科技有限公司,致力于基因和免疫细胞治疗产品的开发。Dr. Lei Yu graduated from Shanghai First Medical College in 1984, majoring in medicine, and obtained his doctorate in medical microbiology and immunology from the University of Alberta in Canada in 1996. In 1999, he served as an associate professor of scientific research in the Department of chemical pharmacy and pharmacy and the Department of bioengineering of the University of Utah. He cooperated with Professor Sun Wang Kim and Professor Henry kopecek, the famous pioneers in the pharmaceutical academic and industrial circles, and established the evaluation and transformation platform of cutting-edge gene therapy technologies and products at that time. In 2000, Dr. Lei Yu joined Nitto Denko Technology Co., Ltd. (short for NDT) as a corporate vice president, focusing on the development, transformation, industrialization and commercialization of biomaterials, biotechnology and cross-border technology modularized biopharmaceuticals. He founded Kinovate Life Science, Inc. in 2004 to accelerate the commercialization of NDT's technologies and products.  Dr. Lei Yu returned to China in 2012 and served as the director of the Institute of Biomedical Engineering and Technology of East China Normal University. He is currently a member of the Shanghai Pharmacy Special Committee and a member of the Shanghai Medical Materials Special Committee. In 2015, Dr. Lei Yu founded Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. and is committed to the development of gene therapy and immune cell therapy products.
发布时间: 2022 - 03 - 16
点击次数: 0
所属职位: 副总经理
所属公司: 上海优卡迪生物医药科技有限公司
个人简介:
同济大学理学学士、金融学硕士,具有15年丰富的资产管理和投融资经验,包括在生物医药和细胞治疗领域的生物技术公司。 目前是优卡迪副总经理,主管公司的投融资和BD业务。Wang graduated from Tongji University and obtained his bachelor of science and master of finance,with 15 years of rich experience in asset management, investment and financing, including biotechnology companies in the field of biomedicine and cell therapy. At present, he is the deputy general manager of Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., in charge of the company's investment and financing and BD business.
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务